Jazz Pharmaceuticals plc (J7Z) - Total Assets
Based on the latest financial reports, Jazz Pharmaceuticals plc (J7Z) holds total assets worth €11.36 Billion EUR (≈ $13.28 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Jazz Pharmaceuticals plc for net asset value and shareholders' equity analysis.
Jazz Pharmaceuticals plc - Total Assets Trend (2013–2024)
This chart illustrates how Jazz Pharmaceuticals plc's total assets have evolved over time, based on quarterly financial data.
Jazz Pharmaceuticals plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Jazz Pharmaceuticals plc's total assets of €11.36 Billion consist of 38.5% current assets and 61.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 20.1% |
| Accounts Receivable | €716.76 Million | 6.0% |
| Inventory | €480.44 Million | 4.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.76 Billion | 39.6% |
| Goodwill | €1.72 Billion | 14.3% |
Asset Composition Trend (2013–2024)
This chart illustrates how Jazz Pharmaceuticals plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Jazz Pharmaceuticals plc (J7Z) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jazz Pharmaceuticals plc's current assets represent 38.5% of total assets in 2024, a decrease from 38.6% in 2013.
- Cash Position: Cash and equivalents constituted 20.1% of total assets in 2024, down from 28.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, a decrease from 56.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 39.6% of total assets.
Jazz Pharmaceuticals plc Competitors by Total Assets
Key competitors of Jazz Pharmaceuticals plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Jazz Pharmaceuticals plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.65 | 4.26 | 4.34 |
| Quick Ratio | 1.44 | 3.74 | 4.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.48 Billion | €3.36 Billion | €2.19 Billion |
Jazz Pharmaceuticals plc - Advanced Valuation Insights
This section examines the relationship between Jazz Pharmaceuticals plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.52 |
| Latest Market Cap to Assets Ratio | 0.74 |
| Asset Growth Rate (YoY) | 5.4% |
| Total Assets | €12.01 Billion |
| Market Capitalization | $8.86 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Jazz Pharmaceuticals plc's assets below their book value (0.74x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jazz Pharmaceuticals plc's assets grew by 5.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jazz Pharmaceuticals plc (2013–2024)
The table below shows the annual total assets of Jazz Pharmaceuticals plc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €12.01 Billion ≈ $14.04 Billion |
+5.43% |
| 2023-12-31 | €11.39 Billion ≈ $13.32 Billion |
+5.15% |
| 2022-12-31 | €10.84 Billion ≈ $12.67 Billion |
-11.90% |
| 2021-12-31 | €12.30 Billion ≈ $14.38 Billion |
+88.17% |
| 2020-12-31 | €6.54 Billion ≈ $7.64 Billion |
+18.00% |
| 2019-12-31 | €5.54 Billion ≈ $6.48 Billion |
+6.45% |
| 2018-12-31 | €5.20 Billion ≈ $6.08 Billion |
+1.56% |
| 2017-12-31 | €5.12 Billion ≈ $5.99 Billion |
+6.74% |
| 2016-12-31 | €4.80 Billion ≈ $5.61 Billion |
+44.04% |
| 2015-12-31 | €3.33 Billion ≈ $3.90 Billion |
-0.19% |
| 2014-12-31 | €3.34 Billion ≈ $3.90 Billion |
+49.18% |
| 2013-12-31 | €2.24 Billion ≈ $2.62 Billion |
-- |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LG… Read more